CN101337922A - Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof - Google Patents
Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof Download PDFInfo
- Publication number
- CN101337922A CN101337922A CNA2008101449597A CN200810144959A CN101337922A CN 101337922 A CN101337922 A CN 101337922A CN A2008101449597 A CNA2008101449597 A CN A2008101449597A CN 200810144959 A CN200810144959 A CN 200810144959A CN 101337922 A CN101337922 A CN 101337922A
- Authority
- CN
- China
- Prior art keywords
- alpha
- piperidino
- acetic acid
- type
- hydroxybutyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention relates to III type 4-[4-[4-(hydroxy diphenyl methyl)-1- piperidyl]-1- hydroxy butyl]-alpha, alpha-dimethyl phenylaceticacidhydrochloride, and pharmaceutical compositions including the compound of antiallergic effective dose and inert carriers mixed or combined with the compound.
Description
The application is dividing an application of No. 200610103142.6, application for a patent for invention of the same name, this application be No. 95193122.9 applications divide an application divide an application original bill international application no PCT/US95/04942,28 days April nineteen ninety-five of international application.
The present invention relates to the new preparation method of the anhydrous and hydrate forms of piperidine derivative, its polymorph and pseudomorphy thing, they can be used as antihistaminic agent, anti-allergic agent and bronchodilator [U.S. Patent No. 4,254,129, on March 3rd, 1981, U.S. Patent No. 4,254,130, on March 3rd, 1981 and U.S. Patent No. 4,285, on April 25th, 958,1981].
The invention provides the anhydrous pharmaceutically acceptable acid additive salt of following formula piperidine derivative and its pharmacologically acceptable salt with and the preparation method of single optical isomer:
Wherein
R
1Expression hydrogen or hydroxyl;
R
2Expression hydrogen; Or
R
1And R
2Having R together
1And R
2Carbon atom between form second key;
N represents the integer of 1-5;
R
3Expression-CH
2OH ,-COOH or-the COO alkyl, moieties wherein has 1-6 carbon atom and is straight or branched;
Each A represents hydrogen or hydroxyl;
This method comprises that the pharmaceutically acceptable acid additive salt that makes corresponding hydration carries out component distillation.
In addition, the present invention also provide the anhydrous pharmaceutically acceptable acid additive salt of preparation following formula piperidine derivative and its pharmacologically acceptable salt with and the method for single optical isomer:
Wherein
R
1Expression hydrogen or hydroxyl;
R
2Expression hydrogen; Or
R
1And R
2Having R together
1And R
2Carbon atom between form second key;
N represents the integer of 1-5;
R
3Expression-CH
2OH ,-COOH or-the COO alkyl, moieties wherein has 1-6 carbon atom and is straight or branched;
Each A represents hydrogen or hydroxyl;
This method comprises that the pharmaceutically acceptable acid additive salt that makes corresponding hydration carries out the minimum amount recrystallization.
In addition, the present invention also provide the hydration pharmaceutically acceptable acid additive salt of preparation following formula piperidine derivative and its pharmacologically acceptable salt with and the method for single optical isomer:
Wherein
R
1Expression hydrogen or hydroxyl;
R
2Expression hydrogen; Or
R
1And R
2Having R together
1And R
2Carbon atom between form second key;
N represents the integer of 1-5;
R
3Expression-CH
2OH ,-COOH or-the COO alkyl, moieties wherein has 1-6 carbon atom and is straight or branched;
Each A represents hydrogen or hydroxyl;
This method comprises that the pharmaceutically acceptable acid additive salt that makes corresponding hydration carries out aqueous recrystallization.
And, the invention provides anhydrous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino of representing with I type and III type]-the 1-hydroxybutyl]-α, the preparation method of alpha-alpha-dimethyl phenyl acetic acid hydrochloride polymorph, 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino with the hydration of representing with II type and IV type]-the 1-hydroxybutyl]-α, the preparation method of alpha-alpha-dimethyl phenyl acetic acid hydrochloride polymorph.
I type polymorph can be determined by following characteristics: range estimation fusing point (kapillary) is in about 196-201 ℃ scope; Fusing heat absorption when pushing the beginning outside open is at about 195-199 ℃, and this is by determine with dsc method; Show as shown in table 1ly substantially with the X-ray powder diffraction pattern, wherein XRPD diagram is to adopt the powder diffractometer that Co X-x ray tube source is housed to measure.Sample Co K
α 1Radiation irradiation and XRPD data are collected (orientation that advantage is depended in the variation of intensity basically) in 5-55 ° of 2 θ scopes
Table 1
| Spacing (D-space), dust | Intensity, l/lo, % |
| 1 | 30 |
| 7 | 30 |
| 6.3 | 65 |
| 5.9 | 35 |
| 5.0 | 45 |
| 4.8 | 100 |
| 4.4 | 45 |
| 3.9 | 60 |
| 3.8 | 75 |
| 3.7 | 30 |
III type polymorph can be determined by following characteristics: range estimation fusing point (kapillary) is in about 166-171 ℃ scope; Be lower than about 90 ℃ of heat absorptions that wide region is arranged, the fusing heat absorption when about 166 ℃ of extrapolations begin is by determine with dsc method; Show as shown in table 2ly substantially with the X-ray powder diffraction pattern, wherein XRPD diagram is to adopt the powder diffractometer that Co X-x ray tube source is housed to measure.Sample Co K
α 1Radiation irradiation and XRPD data are collected (orientation that advantage is depended in the variation of intensity basically) in 5-55 ° of 2 θ scopes.
Table 2
| Spacing, dust | Intensity, l/lo, % |
| 9.0 | 95 |
| 4.9 | 100 |
| 4.8 | 35 |
| 4.6 | 25 |
| 4.5 | 25 |
| 3.7 | 25 |
II type polymorph can be determined by following characteristics: range estimation fusing point (kapillary) is in about 100-105 ℃ scope; Be lower than about 100 ℃ of heat absorption and little thermo-negative reaction peaks (about 2 joule/gram) when about 124-126 ℃ of extrapolation begins that big wide region is arranged, this is by determine with dsc method; Show as shown in table 3ly substantially with the X-ray powder diffraction pattern, wherein XRPD diagram is to adopt the powder diffractometer that Co X-x ray tube source is housed to measure.Sample Co K
α 1Radiation irradiation and XRPD data are collected (orientation that advantage is depended in the variation of intensity basically) in 5-55 ° of 2 θ scopes.
Table 3
| Spacing, dust | Intensity, l/lo, % |
| 7.8 | 45 |
| 6.4 | 44 |
| 5.2 | 85 |
| 4.9 | 60 |
| 4.7 | 80 |
| 4.4 | 55 |
| 4.2 | 50 |
| 4.1 | 60 |
| 3.7 | 75 |
| 3.6 | 60 |
| 3.5 | 50 |
IV type polymorph can be determined by following characteristics: range estimation fusing point (kapillary) is in about 113-118 ℃ scope; Be lower than about 100 ℃ of overlapping heat absorptions (peak) that two wide regions are arranged and other heat absorption (peak) during in about 146 ℃ of extrapolation beginnings, this is by determine with dsc method, and the X-ray powder diffraction pattern shows as shown in table 4 substantially, and wherein the XRPD diagram is to adopt the powder diffractometer that Co X-x ray tube source is housed to measure.Sample Co K
α 1Radiation irradiation and XRPD data are collected (orientation that advantage is depended in the variation of intensity basically) in 5-55 ° of 2 θ scopes.
Table 4
| Spacing, dust | Intensity, l/lo, % |
| 10.4 | 60 |
| 7.0 | 45 |
| 6.4 | 50 |
| 5.3 | 100 |
| 5.2 | 55 |
| 4.3 | 75 |
| 4.1 | 50 |
| 4.0 | 45 |
| 3.8 | 60 |
| 3.5 | 55 |
The formula (I) and (II) the pharmaceutically acceptable acid additive salt of compound comprise anhydrous and salt hydration, are meant and salt that any suitable mineral acid or organic acid form.Suitable mineral acid example hydrochloric acid, Hydrogen bromide, sulfuric acid and phosphoric acid.Comprise carboxylic acid such as acetate, propionic acid, oxyacetic acid, lactic acid, pyruvic acid, propanedioic acid, succsinic acid, fumaric acid, oxysuccinic acid, tartrate, citric acid, cyclohexane sulfamic acid, xitix, toxilic acid, hydroxymaleic acid and dihydroxymaleic acid, phenylformic acid, phenylacetic acid, 4-benzaminic acid, 4-hydroxy-benzoic acid, anthranilic acid, styracin, Whitfield's ointment, 4-aminosallcylic acid, 2-phenoxy benzoic acid, 2-acetoxy-benzoic acid and amygdalic acid, sulfonic acid such as methylsulfonic acid with appropriate organic, ethyl sulfonic acid and beta-hydroxy ethyl sulfonic acid.
Terminology used here " hydrate " is meant water and formula (I) or (II) combination of compound, and wherein water keeps the water molecules state, and is absorbed, adsorbs or be included in formula (D or (II) in the crystal lattice of substrate molecule.
Terminology used here " absorption " is meant a kind of like this physical aspect, wherein formula (I) and (II) water molecules in the hydration pharmaceutically acceptable acid additive salt of piperidine derivative be the formula of being dispersed in (I) and (II) surface of the metaborate monohydrate pharmaceutically acceptable acid additive salt of piperidine derivative.
Terminology used here " absorption " is meant a kind of like this physical aspect, wherein formula (I) and (II) water molecules in the hydration pharmaceutically acceptable acid additive salt of piperidine derivative be to be dispersed in whole formula (I) and (II) in the metaborate monohydrate pharmaceutically acceptable acid additive salt of piperidine derivative.
Formula (I) and (II) the hydration pharmaceutically acceptable acid additive salt of piperidine derivative should be in every mole of formula (I) or (II) in the substrate salt 0.10-5 mole of water scope.
Terminology used here " azeotropic mixture " is meant the liquid mixture of two or more materials that work as one matter, and this is meant that the steam that produces by the liquid portion evaporation is identical with the composition of liquid.Constant boiling mixture is compared with other mixture that same material is formed and is shown high or minimum boiling point.
Terminology used here " component distillation " is meant such class distillation, promptly adds the isolating material of a kind of need so that it can form azeotrope with one or more compositions of original stock in mixture.The boiling point of the azeotrope of Xing Chenging is different from original stock like this.Terminology used here " component distillation " also refers to altogether-distillation.Terminology used here " minimum amount recrystallization " is meant that the ratio of anhydrous solvent and substrate hydrate wherein makes the minimum recrystallization of percentage composition of existing water, has therefore induced the precipitation of anhydrous form substrate.
Terminology used here " aqueous recrystallization " is meant following process, wherein or 1) solid matter is dissolved in be enough to will be in its dissolved certain volume water or the water/ORGANIC SOLVENT MIXTURES and reclaim solid matter by evaporating solvent; 2) with being not enough to that its dissolved minimal amount of water or water/ORGANIC SOLVENT MIXTURES are handled solid matter, heating for dissolving and cooling make crystallization or 3) solid matter is dissolved in is enough to obtain crystallizable saturated solution by the part evaporating solvent then in its dissolved certain volume water or the water/ORGANIC SOLVENT MIXTURES.
Terminology used here " crystal aging " is meant with being not enough to that its dissolved minimal amount of water or water/ORGANIC SOLVENT MIXTURES are handled solid matter, perhaps heating or in the method for stirring at room up to required conversion reaction generation.
Terminology used here " anti-solvent " is meant the solvent bad for described material, when time in the solution that it is added to described material can make described species precipitate.
Terminology used here " suitable temperature " is meant is enough to the dissolved temperature and adding anti-solvent or removing altogether by azeotropic-can make the desired substance temperature of precipitation behind solvent.
The anhydrous pharmaceutically acceptable acid additive salt of formula (I) and formula (II) piperidine derivative can be prepared by the hydration pharmaceutically acceptable acid additive salt component distillation that makes corresponding formula (I) and formula (II) piperidine derivative by the hydration pharmaceutically acceptable acid additive salt of corresponding formula (I) and formula (II) piperidine derivative.
For example the hydration pharmaceutically acceptable acid additive salt of suitable formula (I) and formula (II) piperidine derivative is dissolved in and is enough in the solvent or solvent mixture that its dissolved certain volume is suitable.The example of such solvent comprises water, C
1-C
5Alkanol such as methyl alcohol, ethanol, etc.; Ketone solvent such as acetone, methyl ethyl ketone etc.; The mixture of aliphatics fatsolvent such as ethyl acetate, methyl acetate, methyl-formiate, ethyl formate, acetate isopropyl esters etc. and these solvents and water is as acetone, methyl ethyl ketone/water, water/acetone, He Shui/acetone/ethyl acetate.Then, adding in this solution can be with the same solvent or the suitable anhydrous anti-solvent of second section of its dissolved certain volume, reheat to boiling point to be fit to by azeotropic removal of water and other low boiling point solvent.The suitable anhydrous anti-solvent that adopts in component distillation is, for example ketone solvent such as acetone, methyl ethyl ketone etc.; Aliphatics fatsolvent such as ethyl acetate, methyl acetate, methyl-formiate, ethyl formate, acetate isopropyl esters etc.; C
5-C
8Aliphatic solvent such as pentane, hexane etc.; Aliphatic nitrile such as acetonitrile and these solvent mixtures are as acetone/ethyl acetate.Azeotropic mixture by dephlegmate and solvent is up to temperature variation, and temperature variation indicates that azeotropic mixture removes fully.Reaction mixture can reclaim the anhydrous pharmaceutically acceptable acid additive salt that obtains corresponding formula (I) and formula (II) piperidine derivative by for example filtering from conversion zone.
In addition, the anhydrous pharmaceutically acceptable acid additive salt of formula (I) and formula (II) piperidine derivative can carry out the preparation of minimum amount recrystallization by the hydration pharmaceutically acceptable acid additive salt that makes corresponding formula (I) and formula (II) piperidine derivative by the hydration pharmaceutically acceptable acid additive salt of corresponding formula (I) and formula (II) piperidine derivative.
For example the hydration pharmaceutically acceptable acid additive salt of suitable formula (I) and formula (II) piperidine derivative being dissolved in is enough in anhydrous solvent that its dissolved certain volume is suitable or the solvent mixture and reflux.The example of such solvent comprises water, C
1-C
5Alkanol such as methyl alcohol, ethanol, etc.; Ketone solvent such as acetone, methyl ethyl ketone etc.; The mixture of aliphatics fatsolvent such as ethyl acetate, methyl acetate, methyl-formiate, ethyl formate, acetate isopropyl esters etc. and these solvents and water is as acetone, methyl ethyl ketone/water, water/acetone, He Shui/acetone/ethyl acetate.Then, to be enough to the sedimentary amount of anhydrous pharmaceutically acceptable acid additive salt of initiation formula (I) and formula (II) piperidine derivative, adding in this solution can be with the same solvent or the suitable anhydrous anti-solvent of second section of its dissolved certain volume.Suitable anhydrous anti-solvent is, for example ketone solvent such as acetone, methyl ethyl ketone etc.; Aliphatics fatsolvent such as ethyl acetate, methyl acetate, methyl-formiate, ethyl formate, acetate isopropyl esters etc.; The mixture of ketone solvent and aliphatic ester solvent such as acetone/ethyl acetate etc.; C
5-C
8Aliphatic solvent such as pentane, hexane etc.; Aliphatic nitrile such as acetonitrile and these solvent mixtures are as the mixture of acetone/ethyl acetate etc. and water and ketone solvent such as acetone etc.; And water, the mixture such as the acetone/ethyl acetate of ketone solvent and aliphatic ester solvent.Reaction mixture can reclaim the anhydrous pharmaceutically acceptable acid additive salt that obtains corresponding formula (I) and formula (II) piperidine derivative by for example filtering from conversion zone.
Anhydrous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride polymorph (I type and III type) can be by the several different methods preparation of describing in detail below.
From the III type to the I type
For example, anhydrous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (I type) can be by anhydrous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (III type) preparation, promptly make anhydrous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino as mentioned above]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (III type) carries out crystal and wears out and prepare.
From the II type to the III type
In addition, anhydrous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (III type) can be by hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (II type) preparation, promptly as mentioned above by making hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (II type) carries out the minimum amount recrystallization and prepares.
Prepare the I type from the II type
In addition, anhydrous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (I type) can be by hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (II type) preparation, promptly as mentioned above by making hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (II type) carries out the least quantity recrystallization or makes hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (II type) carries out component distillation and prepares.In a preferred embodiment, 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino with the hydration of II type]-the 1-hydroxybutyl]-α, the alpha-alpha-dimethyl phenyl acetic acid hydrochloride is dissolved in is enough to make its dissolved methyl alcohol, in acetone or the methyl ethyl ketone/water, adds methyl ethyl ketone then.
Prepare the I type from the IV type
In addition, anhydrous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (I type) can be by hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (IV type) preparation, promptly as mentioned above by making hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (IV type) carries out the least quantity recrystallization or carries out component distillation preparing.In a preferred embodiment, 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino with the hydration of IV type]-the 1-hydroxybutyl]-α, the alpha-alpha-dimethyl phenyl acetic acid hydrochloride is dissolved in is enough to make its dissolved methyl alcohol, in acetone or the methyl ethyl ketone/water, adds methyl ethyl ketone then.
The hydration pharmaceutically acceptable acid additive salt of formula (I) piperidine derivative can be by R wherein
3Be-corresponding formula (II) compound of COO alkyl, promptly by appropriate reductant R wherein
3Be-corresponding formula (II) compound of COO alkyl reduces, reductive agent such as sodium borohydride, lithium borohydride, sodium cyanoborohydride or tetramethyl-ammonium borohydride, this reaction is at suitable solvent such as methyl alcohol, ethanol, Virahol or n-propyl alcohol, in the mixture or its basic solution of they and water, under about 0 ℃-solvent refluxing temperature, carry out, and the reaction times changed between about 1/2 hour-8 hours.After suitable sour example hydrochloric acid quenching and acidifying, the hydration pharmaceutically acceptable acid additive salt of recovery type (I) piperidine derivative from conversion zone by crystallization or filtration.
In addition, the hydration pharmaceutically acceptable acid additive salt of formula (I) and formula (II) piperidine derivative can promptly be carried out aqueous recrystallization by the anhydrous pharmaceutically acceptable acid additive salt that makes formula (I) and formula (II) piperidine derivative and be prepared by the anhydrous pharmaceutically acceptable acid additive salt preparation of corresponding formula (I) and formula (II) piperidine derivative.
For example, with being enough to that its dissolved minimal volumes water or suitable water/ORGANIC SOLVENT MIXTURES are handled the suitable formula (I) and the anhydrous pharmaceutically acceptable acid additive salt and the reflux of formula (II) piperidine derivative.Reaction mixture is by for example filtering the hydration pharmaceutically acceptable acid additive salt of recovery type from conversion zone (I) and formula (II) piperidine derivative.Perhaps, with being enough to that its dissolved certain volume water or suitable water/ORGANIC SOLVENT MIXTURES are handled the suitable formula (I) and the anhydrous pharmaceutically acceptable acid additive salt of formula (II) piperidine derivative, and water or water/organic solvent partially or completely is evaporated to certain volume, make the crystallization of hydration pharmaceutically acceptable acid additive salt of initiation formula (I) and formula (II) piperidine derivative.Used suitable solvent is water, acetone, ethanol/water, methyl ethyl ketone/aqueous methanol, methyl ethyl ketone/water etc. in the recrystallization of front.
Hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the pseudomorphy shape thing form of alpha-alpha-dimethyl phenyl acetic acid hydrochloride (II type and IV type) can be by following several different methods preparation.
Ethyl ester/ketone is to the II type
Hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (IV type) is by 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-1-oxo butyl]-α, the alpha-alpha-dimethyl phenyl acetic acid ethyl ester, the preparation of hydrochloride or its free alkali, promptly according to above-mentioned from R wherein
3Be-general method of the hydration pharmacologically acceptable salt acid salt of corresponding formula (II) compound formula (I) piperidine derivative of COO alkyl carries out, but in 1 minute-45 minutes, add entry fast and carrying out in-20 ℃-Yue 50 ℃ of scopes approximately, precipitation obtains hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (II type).
Ethyl ester/ketone is to the IV type
Hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (IV type) is by 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-1-oxo butyl]-α, the alpha-alpha-dimethyl phenyl acetic acid ethyl ester, the preparation of hydrochloride or its free alkali, promptly by aforesaid from R wherein
3Be-general method of the hydration pharmacologically acceptable salt acid salt of corresponding formula (II) compound formula (I) piperidine derivative of COO alkyl carries out, but in about 30 minutes-24 hours, slowly add entry and in about 0 ℃ of-50 ℃ of scope, carry out, the optional crystal seed of putting into, precipitation obtains hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (IV type).
The I type is to the II type
Hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (II type) can be by anhydrous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (I type) preparation, promptly by making hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (II type) carries out recrystallization as mentioned above and prepares.
II type hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the alpha-alpha-dimethyl phenyl acetic acid hydrochloride also can be prepared as follows: a) make 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino in suitable solvent (for example methyl alcohol, acetone or aqueous sodium hydroxide solution)]-1-oxo butyl]-α, alpha-alpha-dimethyl phenyl acetic acid carbethoxy hydrochloride and appropriate reductant reaction; B) use hcl acidifying; And c) in 1 minute-45 minutes, in preferred 10 minutes-30 minutes,,, more preferably adds entry under 20 ℃ of-40 ℃ of temperature preferably at 0 ℃-40 ℃ at-20 ℃-50 ℃.
II type hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the alpha-alpha-dimethyl phenyl acetic acid hydrochloride also can be prepared as follows: a) make 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino in suitable solvent (for example methyl alcohol, acetone or aqueous sodium hydroxide solution)]-1-oxo butyl]-α, alpha-alpha-dimethyl phenyl acetic acid ethyl ester and appropriate reductant reaction; B) use hcl acidifying; And c) in 1 minute-45 minutes, in preferred 10 minutes-30 minutes,,, more preferably adds entry under 20 ℃ of-40 ℃ of temperature preferably at 0 ℃-40 ℃ at-20 ℃-50 ℃.
IV type hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the alpha-alpha-dimethyl phenyl acetic acid hydrochloride can be prepared as follows: a) make 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino in suitable solvent (for example methyl alcohol, acetone or aqueous sodium hydroxide solution)]-1-oxo butyl]-α, alpha-alpha-dimethyl phenyl acetic acid carbethoxy hydrochloride and appropriate reductant reaction; B) use hcl acidifying; And c) in 30 minutes-24 hours, preferred 1 hour-12 hours, more preferably in 2 hours-8 hours, 0 ℃-50 ℃,, more preferably add entry under 20 ℃ of-40 ℃ of temperature preferably at 10 ℃-40 ℃.
IV type hydration 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the alpha-alpha-dimethyl phenyl acetic acid hydrochloride can be prepared as follows: a) make 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino in suitable solvent (for example methyl alcohol, acetone or aqueous sodium hydroxide solution)]-1-oxo butyl]-α, alpha-alpha-dimethyl phenyl acetic acid ethyl ester and appropriate reductant reaction; B) use hcl acidifying; And c) in 30 minutes-24 hours, preferred 1 hour-12 hours, more preferably in 2 hours-8 hours,,, more preferably adds entry under 20 ℃ of-40 ℃ of temperature preferably at 10 ℃-40 ℃ at 0 ℃-50 ℃.
Starting raw material of the present invention is easy to obtain for those of ordinary skills, for example 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the alpha-alpha-dimethyl phenyl acetic acid ethyl ester, hydrochloride is in US patent 4, state on March 3rd, 1981 in 254,129.
The following examples provide the anhydrous and hydrated form (I) of preparation and (II) the pharmaceutically acceptable acid additive salt of piperidine derivative, its polymorph and pseudomorphous typical method.Be to be understood that these embodiment are illustrative and limit the scope of the invention never in any form.Below used term have specified meaning: " g " is meant gram; " mol " is meant mole; " mmol " is meant mmole; " ml " is meant milliliter; " bp " is meant boiling point; " mp " is meant fusing point; " ℃ " be meant degree centigrade; " mmHg " is meant mmhg; " μ l " is meant microlitre; " μ g " is meant microgram; And " μ M " is meant the micromole.
The dsc analysis adopts TA 2910 DSC to finish with uncovered aluminium dish.Under the nitrogen purge situation sample is heated to 240 ℃ with 5 ℃/minute and 50ml/ minute.
The operation that the X-ray powder diffraction is analyzed is as follows:
Sample is placed the illustrated crystal of measured X RPD (being diffracted to zero) sample box.The XRPD diagram is to adopt the powder diffractometer that Co X-x ray tube source, former smooth monochromator and mirror position device (PSD) are housed to measure.Going into light is to adopt 1 ° of slit of dispersing gauged.Active region correspondence on the PSD about 5 ° of 2 θ.(emission) source be carry out at 35kV and 30mA and sample Co K
α 1Radiation irradiation.The XRPD data be in 5-55 ° of 2 θ scopes speed be 0.25 ° of 2 θ/minute and bandwidth (step width) be to collect under the situation of 0.02 ° of 2 θ.
Adopt bis derivative peak system of selection to measure notable attribute-peak position and intensity.It is reported with I/I.The X-ray peak of expression is greater than 20%.Mandatory selection is interrupted, and intensity is about near 5%.The peak of some is directed responsive to change the advantage that causes owing to crystalline form.This has caused I/I.The variation significantly of value.
Embodiment 1
Preparation II type 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the alpha-alpha-dimethyl phenyl acetic acid hydrochloride
Method A
Make 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-1-oxo butyl]-α, the alpha-alpha-dimethyl phenyl acetic acid ethyl ester, hydrochloride (101.92g, 0.1807mol) and methyl alcohol (510ml) mix and to be incorporated in adding 50% sodium hydroxide (72.27g quick stirring under, 0.90mol), and washing in water (61ml).Reflux 2 hours, also (3.42g 0.0903mol) handles with sodium borohydride to make it to be cooled to 35 ℃.Add entry (100ml) and remain on 35 ℃ 10 hours.Add 37% hydrochloric acid (53.0g) and adjust PH to 11.5, add acetone (26.5ml) and water (102ml).Keep also adjusting PH to 2.5 in 2 hours at 35 ℃ with 37% hydrochloric acid (44.69g).Water (408ml) dilution is cooled to-15 ℃, stirs 1.5 hours also by the suction strainer collecting precipitation.With deionized water (3 * 100ml) washing leaching cakes and vacuum-drying obtain 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the hydrate of alpha-alpha-dimethyl phenyl acetic acid hydrochloride (97.10g).
Method B
With 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-1-oxo butyl]-α, the alpha-alpha-dimethyl phenyl acetic acid ethyl ester, hydrochloride (60.01g, 0.106mol) place flask at the bottom of the 1-L three neck gardens, on flask at the bottom of the garden, load onto mechanical stirrer, the Claisen head, the reflux exchanger of logical nitrogen device is arranged at thermometer and top.Add methyl alcohol (300ml) and open agitator.Water (60ml) dilution oar liquid and at 15-20 minute internal heating to 52-54 ℃.Kept 2 hours at 52 ℃, add then 50% sodium hydroxide (42.54g, 0.532mol).73 ℃ the heating about 1 hour 45 minutes, adopt water-bath to be cooled to be lower than 35 ℃ then, add again sodium borohydride (2.02g, 0.0534mol).Spend the night 35 ℃ of stirrings, handle and stirred 2 hours at 35 ℃ with acetone (15.5ml).With 28% hydrochloric acid (75.27g) acidifying mixture to PH1.85, water (282ml) dilution, stir about 30 minutes and at about 2 hours internal cooling to-15 ℃.Cross filter solid and water (2 * 75ml) and ethyl acetate (2 * 75ml) washing.The solid of vacuum-drying gained and leave standstill obtained 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino in two days]-the 1-hydroxybutyl]-α, the hydrate of alpha-alpha-dimethyl phenyl acetic acid hydrochloride (II type) (57.97g, 91.5%) is fine-powder.
Method C
With 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-1-oxo butyl]-α, alpha-alpha-dimethyl phenyl acetic acid ethyl ester (56.12g, 0.1064mol) place flask at the bottom of the 1-L three neck gardens, on flask at the bottom of the garden, load onto mechanical stirrer, the Claisen head, the reflux exchanger of logical nitrogen device is arranged at thermometer and top.Add methyl alcohol (300ml) and open agitator.Water (60ml) dilutes oar liquid and adopts heating mantles to be heated backflow by Therm-O-Watch.When mixture reached about 35 ℃, (34.05g 0.4256mol) handled also water (42ml) rinsing with 50% sodium hydroxide.Reflux to stir 2 hours 15 minutes, at 1 hour internal cooling to 35 ℃, (2.02g 0.0534mol) handles to use sodium borohydride again.Stir not add in 7.5 hours and be stirred in room temperature and left standstill 1.75 days.When mixture reaches 35 ℃ with acetone (15.5ml, 0.21mol) quenching and stirring 2 hours.Add entry (60ml) and regulate PH to 2.5 with 32% hydrochloric acid (65.22g).Be cooled to 40 ℃ and water (25ml) rinsing PH probe.In about 30 minutes, add entry (192ml) and under 33 ℃ of temperature, kept 10 minutes, add a spot of crystal seed.In about 45 minutes, oar liquid is cooled to-12 ℃ also by filtering separation solid (586.2g).(ethyl acetate (100ml is chilled to-10 ℃ in advance) washing is used in 2 * 100ml) washings to water then.Vacuum-drying (133.32 pascals, 50 ℃) is spent the night and is obtained 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the hydrate of alpha-alpha-dimethyl phenyl acetic acid hydrochloride (II type) (58.86g, 98%) is white solid.
Embodiment 2
Preparation IV type 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (IV type)
With 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-1-oxo butyl]-α, alpha-alpha-dimethyl phenyl acetic acid ethyl ester (56.12g, 0.1064mol) place flask at the bottom of the 1-L three neck gardens, on flask at the bottom of the garden, load onto mechanical stirrer, the Claisen head, the reflux exchanger of logical nitrogen device is arranged at thermometer and top.Add methyl alcohol (300ml) and open agitator.Water (60ml) dilutes oar liquid and adopts heating mantles to be heated backflow by Therm-O-Watch.When mixture reached about 35 ℃, (34.05g 0.4256mol) handled also water (42ml) rinsing with 50% sodium hydroxide.Reflux to stir 2 hours 15 minutes, at 1 hour internal cooling to 35 ℃, (2.02g 0.0534mol) handles to use sodium borohydride again.Stir not add in 7.5 hours and be stirred in room temperature and left standstill 1.75 days.When mixture reaches 35 ℃ with acetone (15.5ml, 0.21mol) quenching and stirring 2 hours.Add entry (60ml) and regulate PH to 2.5 with 32% hydrochloric acid (65.22g).Be cooled to 40 ℃ and water (25ml) rinsing PH probe.Under 33 ℃ of temperature, kept 10 minutes, and added a spot of crystal seed and add entry (192ml) in about 4 hours at 35 ℃.In about 45 minutes, oar liquid is cooled to-12 ℃ also by filtering separation solid (586.2g).(ethyl acetate (100ml is chilled to-10 ℃ in advance) washing is used in 2 * 100ml) washings to water then.Vacuum-drying (133.32 pascals, 50 ℃) is spent the night and is obtained 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the hydrate of alpha-alpha-dimethyl phenyl acetic acid hydrochloride (IV type); Mp115-116 ℃ (decomposition).
XRPD: table 5
Table 5
| Spacing, dust | Intensity, l/lo, % |
| 10.38 | 60 |
| 6.97 | 45 |
| 6.41 | 50 |
| 5.55 | 30 |
| 5.32 | 100 |
| 5.23 | 55 |
| 5.11 | 35 |
| 4.98 | 25 |
| 4.64 | 30 |
| 4.32 | 35 |
| 4.28 | 75 |
| 4.12 | 50 |
| 4.02 | 45 |
| 3.83 | 60 |
| 3.65 | 20 |
| 3.51 | 55 |
| 3.46 | 25 |
| 2.83 | 20 |
Embodiment 3
The II type is to I type 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the conversion of alpha-alpha-dimethyl phenyl acetic acid hydrochloride (I type)
Handle 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino with deionized water (2g)]-the 1-hydroxybutyl]-α, (20.0g 0.0355mol) and under agitation adds small amount of acetone (60ml) in the several minutes to the hydrate of alpha-alpha-dimethyl phenyl acetic acid hydrochloride (II type).Filter and with acetone (30ml) washing leaching cake by flocculating aids.With acetone (22ml) washing leaching cake, backflow filtrate, slowly add ethyl acetate (32ml is in 15 minutes) then and keep mixture to reflux.Refluxed 10 minutes, and slowly added other ethyl acetate (23ml is in 10 minutes) then and also refluxed again 15 fens.Add other ethyl acetate (60ml is in 5-10 minute) and continue and refluxed 15 minutes.Be cooled to about 8 ℃ with ice bath, cross filter solid and use ethyl acetate (85ml) washing.Obtained title compound (18.16g, 95%) in 1.5 hours 55 ℃ of vacuum-dryings.
Embodiment 4
The II type is to I type 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the conversion of alpha-alpha-dimethyl phenyl acetic acid hydrochloride
Method A
Handle 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino with methyl ethyl ketone (130ml)]-the 1-hydroxybutyl]-α, and alpha-alpha-dimethyl phenyl acetic acid hydrochloride hydrate (II type) (5.00g, 0.0083mol).Slowly add entry (0.4ml), filter and with methyl ethyl ketone (20ml) washing leaching cake by flocculating aids.Reflux also boils off the 75ml solvent, is cooled to-15 ℃ and collect by suction filtration.(2 * 10ml) washings also obtain title compound (4.33g, 97%) 60 ℃ of vacuum-dryings with methyl ethyl ketone; Mp196-198 ℃.
Method B
With acetone (60ml)) handle 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride hydrate (II type) is (1.4g) and reflux.(88/12: acetone :/water) the form steaming makes volume be reduced to about 35ml except that all water with azeotrope.Cooling solution is also collected title compound, is solid crystal.
Method C
Mix 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, and alpha-alpha-dimethyl phenyl acetic acid hydrochloride hydrate (II type) (53.88g, 0.100mol) and add entry (4.79g) and methyl ethyl ketone (240ml).Stirring occurs up to the pulpous state solid, and adds other methyl ethyl ketone (1L).Stirred 0.5 hour, and filtered by the flocculating aids plate, be transferred to methyl ethyl ketone (100ml) washing leaching cake and with filtrate and washing lotion thermometer is housed, the 2L of mechanical stirrer and still head is in-the three-necked flask.Steam to remove the 721ml methyl ethyl ketone altogether, be cooled to 40 ℃ and stirred 1 hour.Be cooled to-15 ℃ and kept 10 minutes.Also (2 * 65ml) wash, and spending the night 55 ℃ of vacuum-dryings obtains title compound (52.76g, 97.9%) with methyl ethyl ketone to collect solid by suction filtration; Mp197.5-200 ℃.
Method D
Water (8.30g; During water in considering salt hydrate, calculating the water yield is to make the weight of water account for 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, when the alpha-alpha-dimethyl phenyl acetic acid hydrochloride hydrate is anhydrous 17% of weight) handle 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride hydrate (II type) (40.0g, 0.0696mol, measuring purity and be at 93.6% o'clock has 0.89g water to exist, and 35.1g, 0.0575mol, be to have 2.47g water exist at 88.0% o'clock at purity testing).Add methyl ethyl ketone (about 500ml) and stir and dissolve up to most solid.In about 10 minutes, add other in batches methyl ethyl ketone (700ml) and continue stirring 0.5 hour.Filter by the flocculating aids thin plate, with other methyl ethyl ketone (100ml) washing leaching cake, and filtrate and washing lotion is transferred to the thermometer that is equipped with that can roughly regulate the reflux rate ratio, mechanical stirrer, in the Kjeldahl flask of heating mantles and 12-plateOldershow (vacuum envelope) distillation column and still head, use methyl ethyl ketone (100ml) washing again.Steam and remove the 450ml solvent, be cooled to-15 ℃ and also cross filter solid.(2 * 100ml) washings and drying obtain title compound (68.3g, 99.9%) with methyl ethyl ketone; Mp197-199 ℃.
Method E
Make methyl ethyl ketone (4ml) boiling and add 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (500mg).Decant falls the upper strata and add methyl ethyl ketone (3ml) in water layer.Make solution boiling reach 79 ℃, make volume reduce 25%, remove thermal source and cover with aluminium foil up to solution.Make the solution cooling, the crystallization and the dry air of filtering gained obtain title compound.
Embodiment 5
The I type is to II type 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the conversion of alpha-alpha-dimethyl phenyl acetic acid hydrochloride hydrate
Method A
Handle 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino with ethanol (4ml) and deionized water (20ml)]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (I type) is (2.0g).80 ℃ of heating up to forming solution, then stirring at room 23 hours.Filter the oar liquid of gained, water (also spend the night 35 ℃ of vacuum-dryings, obtains title compound (1.88g) by 2 * 10ml) washings; Mp100-105 ℃.
XRPD: table 6
Table 6
| Spacing, dust | Intensity, l/lo, % |
| 11.41 | 20 |
| 7.98 | 20 |
| 7.83 | 45 |
| 6.58 | 45 |
| 6.42 | 60 |
| 5.66 | 20 |
| 5.52 | 45 |
| 5.39 | 30 |
| 5.23 | 65 |
| 5.14 | 45 |
| 4.86 | 65 |
| 4.72 | 100 |
| 4.45 | 65 |
| 4.40 | 45 |
| 4.32 | 45 |
| 4.18 | 45 |
| 4.06 | 65 |
| 4.02 | 55 |
| 3.85 | 25 |
| 3.79 | 75 |
| 3.74 | 95 |
| 3.61 | 80 |
| 3.56 | 25 |
| 3.47 | 65 |
| 3.41 | 20 |
| 2.74 | 20 |
Method B
Make water (35.5ml), methyl alcohol (26.3ml) and sodium-chlor (2.59g) mix.Add 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (I type) is (4.77g).Reflux is up to dissolving and being cooled to-10 ℃ in vapor bath.Filter the solid of gained, water (spend the night and obtain title compound (4.80g) by 2 * 25ml) washings and vacuum-drying.
Embodiment 6
The II type is to III type 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the conversion of alpha-alpha-dimethyl phenyl acetic acid hydrochloride (III type)
With 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the hydrate of alpha-alpha-dimethyl phenyl acetic acid hydrochloride (II type) (55.56g, 0.0929mol, 10% water is arranged) and place pressure bottle with water (2.96g) and acetone (38.1g).With the bottle tight seal and be heated to about 80 ℃.Be cooled to about 50 ℃, on thick agglomerating glass funnel, filter and dilute with acetone (90g) by flocculating aids.With the substance transfer of gained to mechanical stirrer is housed, in the 1L flask of thermometer and reflux exchanger.The reflux mixture also makes it to cool off and stirred weekend.Be cooled to-15 ℃ and on thick agglomerating glass funnel, filtering, with ethyl acetate (2 * 50ml) washings and 50 ℃ of vacuum-dryings.
The most of solid (45.24g) that obtains placed mechanical stirrer is housed, the 500ml three-necked flask of thermometer and reflux exchanger.Add acetone (240ml) and the water (4.82g) and the mixture overnight that refluxes.Make oar liquid be cooled to 35 ℃ and place ice bath and be cooled to be lower than 5 ℃.On thick agglomerating glass funnel, filter and wash, obtain title compound, be white crystalline powder (43.83g, 97%) 50 ℃ of vacuum-drying a few hours with ethyl acetate (50ml); Mp166.5-170.5 ℃.
XRPD: table 7
Table 7
| Spacing, dust | Intensity, l/lo, % |
| 8.95 | 95 |
| 4.99 | 20 |
| 4.88 | 100 |
| 4.75 | 35 |
| 4.57 | 25 |
| 4.47 | 25 |
| 4.46 | 20 |
| 3.67 | 20 |
| 3.65 | 25 |
Embodiment 7
The III type is to I type 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the conversion of alpha-alpha-dimethyl phenyl acetic acid hydrochloride (I type)
With 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, alpha-alpha-dimethyl phenyl acetic acid hydrochloride (III type) (40.0g, be the wet cake of ethyl acetate-dry base of 27.9g) place mechanical stirrer is housed, the 1L1 three-necked flask of thermometer and reflux exchanger.Added acetone (240ml) and reflux mixture about 20 hours, the oar liquid of gained is cooled to-15 ℃ and filtering on thick agglomerating glass funnel.Spend the night with ethyl acetate (50ml) washing and vacuum-drying and to obtain title compound (26.1g, 93.7%); Mp197.5-199.5 ℃
XRPD: table 8
Table 8
| Spacing, dust | Intensity, l/lo, % |
| 11.75 | 35 |
| 7.23 | 35 |
| 6.24 | 60 |
| 5.89 | 40 |
| 5.02 | 20 |
| 4.94 | 30 |
| 4.83 | 100 |
| 4.44 | 30 |
| 3.93 | 75 |
| 3.83 | 20 |
| 3.77 | 85 |
| 3.71 | 25 |
| 3.62 | 30 |
| 3.32 | 25 |
| 3.31 | 20 |
Embodiment 8
The IV type is to I type 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the conversion of alpha-alpha-dimethyl phenyl acetic acid hydrochloride (I type)
With 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the hydrate of alpha-alpha-dimethyl phenyl acetic acid hydrochloride (IV type) (54.35g, 0.0970mol, have 4% water) and place pressure bottle with water (4.16g) and acetone (38.1g).With the bottle tight seal and be heated to about 80 ℃.Be cooled to be lower than about 60 ℃, on thick agglomerating glass funnel, filter and with acetone (32.4g) rinsing filter cake by flocculating aids.Acetone (215g) is added to the mechanical stirrer that is equipped with that contains a small amount of I N-type waferN, in the 1L flask of thermometer and reflux exchanger and reflux.In about 10 minutes with a part of 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the hydrate of alpha-alpha-dimethyl phenyl acetic acid hydrochloride (IV type) acetone solution (47.65g) is added in the acetone of backflow.In 45 minutes, slowly add ethyl acetate (157.5g), add remaining 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino then]-the 1-hydroxybutyl]-α, the acetone solution of the hydrate of alpha-alpha-dimethyl phenyl acetic acid hydrochloride (IV type) is with the acetone rinsing of about 20ml.Add other ethyl acetate in during 45 minutes-1 hour, keep oar liquid to reflux.Stirred 15 minutes, be cooled to-15 ℃ and on the thick agglomerating glass funnel of 350ml the vacuum filtration white solid.(2 * 50ml) washing solids and vacuum-drying are spent the night and are obtained title compound (50.36g, 97%) with ethyl acetate; Mp198-199.5 ℃.
XRPD: table 9
Table 9
| Spacing, dust | Intensity, l/lo, % |
| 14.89 | 20 |
| 11.85 | 20 |
| 7.30 | 20 |
| 6.28 | 70 |
| 5.91 | 25 |
| 5.55 | 20 |
| 5.05 | 25 |
| 4.96 | 55 |
| 4.85 | 100 |
| 4.57 | 45 |
| 4.45 | 55 |
| 3.94 | 45 |
| 3.89 | 20 |
| 3.84 | 20 |
| 3.78 | 60 |
| 3.72 | 35 |
| 3.63 | 20 |
| 3.07 | 20 |
| 3.04 | 20 |
| 2.45 | 20 |
Polymorph of the present invention and pseudomorphous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the alpha-alpha-dimethyl phenyl acetic acid hydrochloride compound can be used as antihistaminic agent, anti-allergic agent and bronchodilator, and can use separately or use with pharmaceutically acceptable carrier, can use as tablet capsule, pulvis with solid or liquid form, solution, suspension or emulsion form.
Polymorph of the present invention and pseudomorphous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the alpha-alpha-dimethyl phenyl acetic acid hydrochloride compound can be oral, non-enteron aisle is used as subcutaneous, vein, intramuscular, intraperitoneal and is used, uses by instillation in the nose or by mucous membrane, for example is administered to nose, larynx and bronchial mucous membrane to contain the short grained aerosol propellant of The compounds of this invention with spraying or dry powdered form.
Used polymorph and pseudomorphous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the amount of alpha-alpha-dimethyl phenyl acetic acid hydrochloride compound depends on patient and the mode used and can be any significant quantity.The polymorph of being used and pseudomorphous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the amount of alpha-alpha-dimethyl phenyl acetic acid hydrochloride compound changes in a very wide scope, and the unitary dose that significant quantity promptly is provided is in that about 0.01-20mg/kg patient body weight/sky can reach required effect.For example required antihistamine, antianaphylaxis and bronchiectatic activity can contain 1-500mg polymorph of the present invention and pseudomorphous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino by taking]-the 1-hydroxybutyl]-α, the unit dosage form of alpha-alpha-dimethyl phenyl acetic acid hydrochloride compound such as tablet, take 1-4 time and realize every day.
The solid dosage form can be conventional form.Therefore, solid form can be and contains polymorph of the present invention and pseudomorphous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the capsule of the common gelatin form of alpha-alpha-dimethyl phenyl acetic acid hydrochloride compound and carrier, carrier such as lubricant and inert filler such as lactose, sucrose and W-Gum.On the other hand can be with polymorph and pseudomorphous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the alpha-alpha-dimethyl phenyl acetic acid hydrochloride compound is made tablet with the conventional tablet carrier, conventional tablet carrier such as lactose, sucrose or W-Gum or gelatin, disintegrating agent such as W-Gum, potato starch or alginic acid and lubricant such as stearic acid or Magnesium Stearate.
Polymorph of the present invention and pseudomorphous 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the alpha-alpha-dimethyl phenyl acetic acid hydrochloride compound also can the injection form, use by the physiologically acceptable dilution of described compound and the solution or the suspension of pharmaceutically acceptable carrier, pharmaceutically acceptable carrier can be aseptic liquid Ru Shui and oil, is added with or is not added with tensio-active agent and other pharmaceutically acceptable assistant agent.Available oil illustrates as follows: sherwood oil, animal, plant or synthetic oil, for example peanut oil, soybean oil or mineral oil.Generally speaking, water, salt solution, the aqueous solution of dextrose and associated sugars and dibasic alcohol such as propylene glycol and polyoxyethylene glycol are preferred liquid vehicles, are like this for injection liquid especially.
The aerosol that The compounds of this invention uses with solution or form of suspension can be packed in the pressurised aerosol container with suitable propelling agent and available assistant agent, suitable propelling agent such as hydrocarbon propellants such as propane, butane or Trimethylmethane, it can non-pressurized form be used as to use in atomizer or the sprinker.The terminology used here patient is meant warm-blooded animal, bird, Mammals, for example people, cat, dog, horse, goat, ox, pig, lamb, rat, mouse and cavy.
Claims (2)
1.III type 4-[4-[4-(hydroxyl diphenyl methyl)-piperidino]-the 1-hydroxybutyl]-α, the alpha-alpha-dimethyl phenyl acetic acid hydrochloride.
2. contain the antianaphylaxis significant quantity claim 1 compound and mix with it or the pharmaceutical composition of bonded inert support.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24573194A | 1994-05-18 | 1994-05-18 | |
| US08/245,731 | 1994-05-18 | ||
| US08/417,161 | 1995-04-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95193122A Division CN1148849A (en) | 1994-05-18 | 1995-04-28 | Process for preparing anhydrous and hydrate forms of antihistaminic pipeeridine derivatives, polymorphs and spseudormophs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101337922A true CN101337922A (en) | 2009-01-07 |
Family
ID=22927849
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100059112A Expired - Lifetime CN101497581B (en) | 1994-05-18 | 1995-04-28 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
| CNA2008101449597A Pending CN101337922A (en) | 1994-05-18 | 1995-04-28 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100059112A Expired - Lifetime CN101497581B (en) | 1994-05-18 | 1995-04-28 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN101497581B (en) |
| ZA (1) | ZA953930B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4254129A (en) * | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
| US4285957A (en) * | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof |
-
1995
- 1995-04-28 CN CN2009100059112A patent/CN101497581B/en not_active Expired - Lifetime
- 1995-04-28 CN CNA2008101449597A patent/CN101337922A/en active Pending
- 1995-05-15 ZA ZA953930A patent/ZA953930B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101497581A (en) | 2009-08-05 |
| CN101497581B (en) | 2012-07-11 |
| ZA953930B (en) | 1996-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1907967B (en) | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof | |
| CN104797574A (en) | LFA-1 inhibitor and polymorph thereof | |
| JP2009040783A (en) | Polymorphic crystal of donepezil hydrochloride and process for producing the same | |
| WO2018171816A1 (en) | Deuterated dipeptide boronic acid or ester compound thereof, and synthesis method and application thereof | |
| JP2005350459A (en) | Polymorph of fexofenadine and method for producing the same | |
| CA2022236A1 (en) | Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders | |
| CN101497581B (en) | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof | |
| TW412527B (en) | Novel 4-diphenylmethyl piperidine derivatives | |
| WO2011158262A1 (en) | Polymorphic form of fexofenadine hydrochloride, intermediates and process for its preparation | |
| EP0367944A2 (en) | Ether derivative of 4-[3H] -quinazolinone, a process for the preparation thereof, and pharmaceutical compositions | |
| JPH07252213A (en) | Tosyl acid suplatast having excellent absorbability and its production | |
| HU227539B1 (en) | Polymorphs of donepezil hydrochloride and process for production and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1129097 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20090107 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1129097 Country of ref document: HK |